Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

NCT02232386 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocyte Leukemia
Adult Patients

Interventions

DRUG: Ibrutinib
DRUG: Rituximab

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto